What is Zyn and why is the FDA reviewing it?

Zyn is a flavored nicotine pouch product that Philip Morris International wants to advertise as a less harmful alternative for adult smokers. The FDA is reviewing this request to assess its validity and impact.

How popular are Zyn nicotine pouches?

Zyn is the leading brand in the rapidly growing nicotine pouch market, achieving over $3.24 billion in sales last year and dominating more than two-thirds of the U.S. market share.

What are the concerns about Zyn, according to anti-tobacco groups?

Anti-tobacco groups are concerned about the appeal of Zyn to young people and nonsmokers, citing viral social media content and potential spikes in product sales following popular online trends.

Home / Health / Zyn Pouches: FDA Weighs 'Reduced Risk' Claims

Zyn Pouches: FDA Weighs 'Reduced Risk' Claims

22 Jan

•

Summary

FDA considers advertising Zyn pouches as less harmful than cigarettes.
Zyn sales exceeded $3.24 billion last year, dominating the market.
Concerns exist about potential harm to young people and nonsmokers.

Zyn Pouches: FDA Weighs 'Reduced Risk' Claims

The U.S. Food and Drug Administration (FDA) is convening a public meeting to evaluate Philip Morris International's proposal to market its Zyn nicotine pouches as a reduced-risk product for adult smokers. The agency's preliminary review suggests regulators may approve the claims, which would allow Zyn to be advertised as reducing risks of mouth cancer, heart disease, and lung cancer associated with smoking.

Zyn has experienced explosive growth, generating over $3.24 billion in sales last year and securing more than two-thirds of the nicotine pouch market. This surge is occurring in a shrinking tobacco industry, with Zyn representing a significant growth area. Despite its success, the FDA must also assess potential harms, particularly concerning youth uptake, fueled partly by viral social media content.

FDA scientists have indicated that the assertion of Zyn reducing smoking-related illnesses is scientifically accurate, based on available data that suggests the pouches contain minimal harmful chemicals. While Zyn was authorized to remain on the market in January, the current review focuses on specific marketing language. The FDA panel of independent health experts will offer recommendations, though the agency is not bound by their advice and faces no deadline for a final decision.